|By Marketwired .||
|May 7, 2014 10:05 AM EDT||
BETHLEHEM, PA -- (Marketwired) -- 05/07/14 -- Fresh from the American Academy of Neurology Annual Meeting (#AANAM) last week in Philadelphia, Cerora, Inc. (@Cerora1), a StartUp Health / GE Healthcare Entrepreneurship program and Ben Franklin Technology Partners of Northeastern Pennsylvania company, reported on the successful debut of their Qumpass neuro/psychological testing software which provides essential data to inform clinicians making the unfortunately under-investigated 'Return-to-Learn' decision for concussion assessment and management. The Qumpass software's built-in team data acquisition and extended team communication functions greatly enhance clinical evidence development and communication between the family, medical team and school teams. Interaction from all three groups more comprehensively addresses important issues in concussion and brain injury decision making.
"Although there are hundreds of papers on 'Return-to-Play,' there are very few, if any, papers providing clinical evidence to investigators and physicians regarding 'Return-to-Learn.' Qumpass has been designed to generate this kind of evidence and provide the medical community with actionable information on how best to manage a student's return to the classroom after a TBI or concussion," commented Dr. Adam Simon, Cerora CEO. "Last week at the AAN Annual Meeting, Cerora had a wonderful interaction with the neurology community both at our three scientific presentations and at our exhibit booth, and our Company actively raised awareness of this tremendously important decision within the concussion / brain injury diagnostic challenge."
"Unfortunately, there are no accepted diagnostic criteria or electrodiagnostic/ radiographic markers that allow a physician to adequately determine when a student is medically safe to return back to the classroom or to the sports field after a concussive head injury. I am thus greatly enthusiastic by the preliminary research data presented by Cerora at the AAN meeting that suggests that their technology may provide tangible solutions to this unsettling problem," noted Stephen J. Martino, MD, Scientific Advisory Board member to Cerora and AAN member.
Cerora is leading the way in the development of a virtual 'thermometer' for measuring brain function. The company is developing and testing the technologies needed to generate critically important, objective, portable, biosensor-based brain-function diagnostic information that physicians seek. Cerora solutions are designed to directly address the 'Return-to-Learn' decision associated with the management of concussion. Located in the high-tech nexus at Ben Franklin Technology Partners of Northeastern Pennsylvania's TechVentures in Lehigh University's Mountaintop Campus in Bethlehem, Pennsylvania, the Company has assembled a team of experienced medical scientists and management professionals under the leadership of CEO Adam J. Simon, PhD, a noted physicist and globally-recognized brain biomarker expert.
For additional information please visit www.cerora.com.
Follow us on Twitter @Cerora1.
Jan. 19, 2017 06:30 PM EST Reads: 6,313
Jan. 19, 2017 05:30 PM EST Reads: 3,625
Jan. 19, 2017 05:15 PM EST Reads: 3,099
Jan. 19, 2017 05:15 PM EST Reads: 1,291
Jan. 19, 2017 04:45 PM EST Reads: 3,755
Jan. 19, 2017 04:45 PM EST Reads: 3,470
Jan. 19, 2017 04:15 PM EST Reads: 5,403
Jan. 19, 2017 04:00 PM EST Reads: 5,427
Jan. 19, 2017 03:45 PM EST Reads: 1,791
Jan. 19, 2017 03:30 PM EST Reads: 1,031
Jan. 19, 2017 02:15 PM EST Reads: 1,056
Jan. 19, 2017 02:00 PM EST Reads: 4,780
Jan. 19, 2017 01:15 PM EST Reads: 5,669
Jan. 19, 2017 01:15 PM EST Reads: 5,162
Jan. 19, 2017 01:15 PM EST Reads: 3,532